When was Curtana Pharma founded?

Curtana Pharma was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Curtana Pharma located?

Curtana Pharma is headquartered in Austin, United States.

Who is the current CEO of Curtana Pharma?

Gregory Stein of Curtana Pharma.

How many employees does Curtana Pharma have?

As of Apr 30, 2026, the latest employee count at Curtana Pharma is 11.

Is Curtana Pharma a funded company?

Curtana Pharma is a funded company, having raised an undisclosed amount across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 21, 2014.

When was the latest funding round of Curtana Pharma?

Curtana Pharma's latest funding was a $***** Grant (prize money) round on May 31, 2017, with participation from 1 investor.

Where does Curtana Pharma rank among its competitors?

Curtana Pharma ranks 18th amongst 58 active competitors, of which 20 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Trogenix, which secured $95M in Oct, 2025.

Who are the top competitors of Curtana Pharma?

Curtana Pharma's top competitors include Trogenix, OVM and Diakonos. Among them, Trogenix secured the most recent funding round in October, 2025.

Curtana Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Curtana is a US-based, early-stage biopharma developing transcription factor targeting small molecule therapeutics for glioblastoma multiforme. Olig2 is a transcription factor that is essential to normal early brain development but is not found in mature brain cells and non-brain tissue. Curtana’s lead candidate, CT-179, directly targets the OLIG2 transcription factor that is highly expressed in all diffuse gliomas and is found in ~100% of GBM cells that are positive for the tumorigenic CD133 stem cell marker. In Aug.2017, the company completed the Pre-IND Submission for CT-179 for the treatment of Malignant Gliomas.

Key Metrics

Founded Year

2013

Location

Austin, United States

Stage

Seed

Latest Funding Round

Grant (prize money), May 31, 2017, $*****

Investors

Austin Technology Incubator & 8 more

Ranked

18^th among 58 active competitors

Employee Count

11 as on Apr 30, 2026

Similar Companies

Trogenix & 56 more

View Curtana Pharma's full profile

Curtana Pharma has raised funding over 8 rounds. Its first funding round was on Aug 21, 2014. Its latest funding round was a Grant (prize money) round on May 31, 2017 for $*****. 1 investor participated in its latest round. Curtana Pharma has 9 institutional investors.

Here is the list of recent funding rounds of Curtana Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 31, 2017	9925276	Grant (prize money)	8616650	4741727	6858423	1271384
Feb 15, 2017	3242632	Seed	7914314	3208709	5562217	4726633
Feb 01, 2017	2241816	Grant (prize money)	4494328	3774143	3299135	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Curtana Pharma's funding rounds and investors

The founders of Curtana Pharma is Gregory Stein.

Here are the details of Curtana Pharma's key team members:

Gregory Stein: Co-founder, President and CEO of Curtana Pharma.

View details of Curtana Pharma's Founder profiles and Board Members

Curtana Pharma's employee count trend

Curtana Pharma has 11 employees as of Apr 26. Here is Curtana Pharma's employee count trend over the years:

Uncover Curtana Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Curtana Pharma include Trogenix, OVM and Diakonos. Here is the list of Top 10 competitors of Curtana Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Trogenix 2023, Edinburgh (United Kingdom), Series A	Developer of precision cancer treatments using its proprietary gene therapy platform	$111M	IQ Capital, Ain & 9 others	61/100
2nd	OVM 2012, Oxford (United Kingdom), Series B	Therapeutic peptide vaccines for cancer	$15.5M	Dxvx, Oxford University Innovation & 13 others	57/100
3rd	Diakonos 2022, Houston (United States), Seed	Provider of immunotherapeutics for cancer treatment	$31.4M	Restem, Buttonwood Titan QC Fund & 3 others	54/100
4th	Biodexa Pharmaceuticals 2000, Cardiff (United Kingdom), Series A	Developer of therapeutics for the treatment of brain cancer	$6.79M	-	50/100
5th	invIOs 2019, Vienna (Austria), Series A	Developer of immunotherapies for the treatment of cancer	$8.95M	Ligand Pharmaceuticals	45/100
6th	Systimmune 2014, Redmond (United States), Unfunded	Biopharmaceutical company developing innovative antibody-based therapies for cancer treatment	-	-	44/100
7th	CNS Pharmaceuticals 2017, Houston (United States), Public	Developer of treatments for primary and metastatic cancers in the brain and central nervous system	-	Falcon Capital	44/100
8th	OncoSynergy 2011, San Francisco (United States), Acquired	Developer of resistance mechanism inhibitors to treat cancer	$26.7M	Connecticut Innovations, National Cancer Institute ... & 4 others	43/100
9th	Modifi Bio 2021, New Haven (United States), Acquired	Developer of therapeutics for the treatment of cancer	$11.7M	BrightEdge, The Sontag Foundation & 6 others	42/100
10th	Hemerion 2020, Villeneuve d Ascq (France), Series A	Developer of therapeutic solutions for the treatment of cancer	$7.38M	Finovam Gestion, Nord France Amorquage & 2 others	41/100
18th	Curtana Pharma 2013, Austin (United States), Seed	US-based, early-stage biopharma developing transcription factor targeting small molecule therapeutics for glioblastoma multiforme	-	Austin Technology Incubator, Thynk Capital ... & 7 others	34/100